Current Status of Vitamin D Signaling and Its Therapeutic Applications

被引:86
作者
Carlberg, Carsten [1 ]
Molnar, Ferdinand [2 ]
机构
[1] Univ Eastern Finland, Dept Biosci, FIN-70211 Kuopio, Finland
[2] Univ Eastern Finland, Dept Pharm, FIN-70211 Kuopio, Finland
基金
芬兰科学院;
关键词
Crystal structure; gene regulation; genome-wide view; nuclear receptor; vitamin D; vitamin D analogues; vitamin D receptor; LIGAND-BINDING DOMAIN; D NUCLEAR RECEPTOR; 1-ALPHA,25-DIHYDROXYVITAMIN D-3-26,23-LACTONE ANALOGS; PROLIFERATOR-ACTIVATED RECEPTOR; STRUCTURE-BASED DESIGN; D RESPONSE ELEMENTS; SIDE-CHAINS; 1,25-DIHYDROXYVITAMIN D-3; THYROID-HORMONE; GENE-EXPRESSION;
D O I
10.2174/156802612799436623
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Vitamin D and in particular its biologically most active metabolite, 1 alpha,25-dihydroxyvitamin D-3 (1 alpha,25(OH)(2)D-3), are central endocrine molecules that influence many aspects of human physiology, which are not only the well-known calcium and phosphorus up-take and transport controlling bone formation, but also the control of immune functions and of cellular growth and differentiation. Basically all actions of 1 alpha,25(OH)(2)D-3 are mediated by the transcription factor vitamin D receptor (VDR). The crystal structure of the VDR and detailed knowledge on its molecular interactions with the ligand provide significant insight into the mechanisms of vitamin D signaling. This applies also on the action of the huge number of synthetic 1 alpha,25(OH)(2)D-3 analogues, which have been developed with the goal of a therapeutic application in hyper-proliferative diseases, such as psoriasis, benign prostate hyperplasia and different types of cancer, in immune functions, such as autoimmune diseases and microbial infections, or in bone disorders, such as osteoporosis. Moreover, detailed investigations on many VDR target genes and in particular the recently available genome-wide view on vitamin D signaling allows a more complete view on the potential of the nuclear hormone. In this review we discuss the latest insight into vitamin D signaling in context with the most prominent 1 alpha,25(OH)(2)D-3 analogues.
引用
收藏
页码:528 / 547
页数:20
相关论文
共 185 条
[61]   The vitamin D receptor is present in caveolae-enriched plasma membranes and binds 1α,25(OH)2-vitamin D3 in vivo and in vitro [J].
Huhtakangas, JA ;
Olivera, CJ ;
Bishop, JE ;
Zanello, LP ;
Norman, AW .
MOLECULAR ENDOCRINOLOGY, 2004, 18 (11) :2660-2671
[62]   CCAAT/enhancer-binding protein δ:: A molecular target of 1,25-dihydroxyvitamin D3 in androgen-responsive prostate cancer LNCaP cells [J].
Ikezoe, T ;
Gery, S ;
Yin, D ;
O'Kelly, J ;
Binderup, L ;
Lemp, N ;
Taguchi, H ;
Koeffler, HP .
CANCER RESEARCH, 2005, 65 (11) :4762-4768
[63]   22S-Butyl-1α,24R-dihydroxyvitamin D3: Recovery of vitamin D receptor agonistic activity [J].
Inaba, Yuka ;
Nakabayashi, Makoto ;
Itoh, Toshimasa ;
Yoshimoto, Nobuko ;
Ikura, Teikichi ;
Ito, Nobutoshi ;
Shimizu, Masato ;
Yamamoto, Keiko .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2010, 121 (1-2) :146-150
[64]   A New Class of Vitamin D Analogues that Induce Structural Rearrangement of the Ligand-Binding Pocket of the Receptor [J].
Inaba, Yuka ;
Yoshimoto, Nobuko ;
Sakamaki, Yuta ;
Nakabayashi, Makoto ;
Ikura, Teikichi ;
Tamamura, Hirokazu ;
Ito, Nobutoshi ;
Shimizu, Masato ;
Yamamoto, Keiko .
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (05) :1438-1449
[65]  
Institute of Medicine, 2010, DIET REF INT CALC VI
[66]   Translating the histone code [J].
Jenuwein, T ;
Allis, CD .
SCIENCE, 2001, 293 (5532) :1074-1080
[67]   G2/M arrest by 1,25-dihydroxyvitamin D3 in ovarian cancer cells mediated through the induction of GADD45 via an exonic enhancer [J].
Jiang, F ;
Li, PF ;
Fornace, AJ ;
Nicosia, SV ;
Bai, WL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (48) :48030-48040
[68]  
JIANG HP, 1994, ONCOGENE, V9, P3397
[69]   Current understanding of the molecular actions of vitamin D [J].
Jones, G ;
Strugnell, SA ;
DeLuca, HF .
PHYSIOLOGICAL REVIEWS, 1998, 78 (04) :1193-1231
[70]   The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB [J].
Jurutka, PW ;
Remus, LS ;
Whitfield, GK ;
Thompson, PD ;
Hsieh, JC ;
Zitzer, H ;
Tavakkoli, P ;
Galligan, MA ;
Dang, HTL ;
Haussler, CA ;
Haussler, MR .
MOLECULAR ENDOCRINOLOGY, 2000, 14 (03) :401-420